Combination Chemotherapy with S-1 and Docetaxel in Advanced Gastric Cancer patient with Peritoneal Dissemination and Malignant Ascites

Masakatsu Nakamura, Hisakazu Shiroeda, Tomoki Fukuyama, Tomiyasu Arisawa, Jo Yonemura, Tomoyuki Shibata, Tomomitsu Tahara, Daisuke Yoshioka, Masaaki Ohkubo, Akemi Kamatani, Yuuko Katoh, Ichiro Hirata

Research output: Contribution to journalArticle

Abstract

Background; Combined chemotherapy with S-1 and docetaxel was implemented in patient with advanced or recurrent gastric cancer associated with peritoneal dissemination and malignant ascites. Methods; S-1 was administered orally at 80 mg/m2 for 14 consecutive days and docetaxel was administered at 40 mg/m2 on day 1, followed by a 1-week rest, as one course, and the treatment was repeated until progression or severe toxicity. Results; Three out of the five patients showed response to the treatment. The three patients with response had diffuse-type tumor according to the Lauren's classification. The median number of treatment courses was 4. The median survival time was 315 days, the median time to treatment failure was 225 days, and the 1-year survival rate was 20%. Conclusions; These results suggest that combined therapy with S-1 and docetaxel is a promising treatment for advanced or recurrent gastric cancer with malignant ascites and peritoneal dissemination.

Original languageEnglish
Pages (from-to)7-10
Number of pages4
JournalAnnals of Cancer Research and Therapy
Volume20
Issue number1
DOIs
Publication statusPublished - 01-01-2012

Fingerprint

docetaxel
Combination Drug Therapy
Ascites
Stomach Neoplasms
Therapeutics
Treatment Failure
Survival Rate
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Nakamura, Masakatsu ; Shiroeda, Hisakazu ; Fukuyama, Tomoki ; Arisawa, Tomiyasu ; Yonemura, Jo ; Shibata, Tomoyuki ; Tahara, Tomomitsu ; Yoshioka, Daisuke ; Ohkubo, Masaaki ; Kamatani, Akemi ; Katoh, Yuuko ; Hirata, Ichiro. / Combination Chemotherapy with S-1 and Docetaxel in Advanced Gastric Cancer patient with Peritoneal Dissemination and Malignant Ascites. In: Annals of Cancer Research and Therapy. 2012 ; Vol. 20, No. 1. pp. 7-10.
@article{c87313b3b3a6448c88358fd537b8c05e,
title = "Combination Chemotherapy with S-1 and Docetaxel in Advanced Gastric Cancer patient with Peritoneal Dissemination and Malignant Ascites",
abstract = "Background; Combined chemotherapy with S-1 and docetaxel was implemented in patient with advanced or recurrent gastric cancer associated with peritoneal dissemination and malignant ascites. Methods; S-1 was administered orally at 80 mg/m2 for 14 consecutive days and docetaxel was administered at 40 mg/m2 on day 1, followed by a 1-week rest, as one course, and the treatment was repeated until progression or severe toxicity. Results; Three out of the five patients showed response to the treatment. The three patients with response had diffuse-type tumor according to the Lauren's classification. The median number of treatment courses was 4. The median survival time was 315 days, the median time to treatment failure was 225 days, and the 1-year survival rate was 20{\%}. Conclusions; These results suggest that combined therapy with S-1 and docetaxel is a promising treatment for advanced or recurrent gastric cancer with malignant ascites and peritoneal dissemination.",
author = "Masakatsu Nakamura and Hisakazu Shiroeda and Tomoki Fukuyama and Tomiyasu Arisawa and Jo Yonemura and Tomoyuki Shibata and Tomomitsu Tahara and Daisuke Yoshioka and Masaaki Ohkubo and Akemi Kamatani and Yuuko Katoh and Ichiro Hirata",
year = "2012",
month = "1",
day = "1",
doi = "10.4993/acrt.20.07",
language = "English",
volume = "20",
pages = "7--10",
journal = "Annals of Cancer Research and Therapy",
issn = "1344-6835",
publisher = "PJD Publications Ltd",
number = "1",

}

Nakamura, M, Shiroeda, H, Fukuyama, T, Arisawa, T, Yonemura, J, Shibata, T, Tahara, T, Yoshioka, D, Ohkubo, M, Kamatani, A, Katoh, Y & Hirata, I 2012, 'Combination Chemotherapy with S-1 and Docetaxel in Advanced Gastric Cancer patient with Peritoneal Dissemination and Malignant Ascites', Annals of Cancer Research and Therapy, vol. 20, no. 1, pp. 7-10. https://doi.org/10.4993/acrt.20.07

Combination Chemotherapy with S-1 and Docetaxel in Advanced Gastric Cancer patient with Peritoneal Dissemination and Malignant Ascites. / Nakamura, Masakatsu; Shiroeda, Hisakazu; Fukuyama, Tomoki; Arisawa, Tomiyasu; Yonemura, Jo; Shibata, Tomoyuki; Tahara, Tomomitsu; Yoshioka, Daisuke; Ohkubo, Masaaki; Kamatani, Akemi; Katoh, Yuuko; Hirata, Ichiro.

In: Annals of Cancer Research and Therapy, Vol. 20, No. 1, 01.01.2012, p. 7-10.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combination Chemotherapy with S-1 and Docetaxel in Advanced Gastric Cancer patient with Peritoneal Dissemination and Malignant Ascites

AU - Nakamura, Masakatsu

AU - Shiroeda, Hisakazu

AU - Fukuyama, Tomoki

AU - Arisawa, Tomiyasu

AU - Yonemura, Jo

AU - Shibata, Tomoyuki

AU - Tahara, Tomomitsu

AU - Yoshioka, Daisuke

AU - Ohkubo, Masaaki

AU - Kamatani, Akemi

AU - Katoh, Yuuko

AU - Hirata, Ichiro

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background; Combined chemotherapy with S-1 and docetaxel was implemented in patient with advanced or recurrent gastric cancer associated with peritoneal dissemination and malignant ascites. Methods; S-1 was administered orally at 80 mg/m2 for 14 consecutive days and docetaxel was administered at 40 mg/m2 on day 1, followed by a 1-week rest, as one course, and the treatment was repeated until progression or severe toxicity. Results; Three out of the five patients showed response to the treatment. The three patients with response had diffuse-type tumor according to the Lauren's classification. The median number of treatment courses was 4. The median survival time was 315 days, the median time to treatment failure was 225 days, and the 1-year survival rate was 20%. Conclusions; These results suggest that combined therapy with S-1 and docetaxel is a promising treatment for advanced or recurrent gastric cancer with malignant ascites and peritoneal dissemination.

AB - Background; Combined chemotherapy with S-1 and docetaxel was implemented in patient with advanced or recurrent gastric cancer associated with peritoneal dissemination and malignant ascites. Methods; S-1 was administered orally at 80 mg/m2 for 14 consecutive days and docetaxel was administered at 40 mg/m2 on day 1, followed by a 1-week rest, as one course, and the treatment was repeated until progression or severe toxicity. Results; Three out of the five patients showed response to the treatment. The three patients with response had diffuse-type tumor according to the Lauren's classification. The median number of treatment courses was 4. The median survival time was 315 days, the median time to treatment failure was 225 days, and the 1-year survival rate was 20%. Conclusions; These results suggest that combined therapy with S-1 and docetaxel is a promising treatment for advanced or recurrent gastric cancer with malignant ascites and peritoneal dissemination.

UR - http://www.scopus.com/inward/record.url?scp=85024713817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024713817&partnerID=8YFLogxK

U2 - 10.4993/acrt.20.07

DO - 10.4993/acrt.20.07

M3 - Article

AN - SCOPUS:85024713817

VL - 20

SP - 7

EP - 10

JO - Annals of Cancer Research and Therapy

JF - Annals of Cancer Research and Therapy

SN - 1344-6835

IS - 1

ER -